Published in Int J Radiat Oncol Biol Phys on March 01, 2010
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA (2012) 5.90
Estimation of α/β for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys (2011) 2.96
Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT. Int J Radiat Oncol Biol Phys (2015) 2.12
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.76
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys (2013) 1.40
Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. Int J Radiat Oncol Biol Phys (2010) 1.21
The promise of dynamic contrast-enhanced imaging in radiation therapy. Semin Radiat Oncol (2011) 1.12
Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol (2013) 1.09
Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. World J Gastroenterol (2013) 1.06
The first clinical implementation of electromagnetic transponder-guided MLC tracking. Med Phys (2014) 1.03
Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06. Int J Radiat Oncol Biol Phys (2012) 1.00
Normal Tissue Complication Probability (NTCP) modeling of late rectal bleeding following external beam radiotherapy for prostate cancer: A Test of the QUANTEC-recommended NTCP model. Acta Oncol (2010) 0.98
Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126. Int J Radiat Oncol Biol Phys (2015) 0.96
Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum. Ann R Coll Surg Engl (2012) 0.94
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine (2016) 0.90
The clinical impact of the couch top and rails on IMRT and arc therapy. Phys Med Biol (2011) 0.89
Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. Radiat Oncol (2013) 0.89
Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis. J Radiat Res (2014) 0.87
Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study. Radiat Oncol (2010) 0.87
Multivariate normal tissue complication probability modeling of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer. Radiat Oncol (2013) 0.87
Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer. J Radiat Res (2013) 0.86
Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer. J Radiat Res (2014) 0.86
Dose/volume-response relations for rectal morbidity using planned and simulated motion-inclusive dose distributions. Radiother Oncol (2013) 0.85
A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer. Radiat Oncol (2012) 0.85
Preliminary analysis of risk factors for late rectal toxicity after helical tomotherapy for prostate cancer. J Radiat Res (2013) 0.85
Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer. Prostate Cancer (2012) 0.84
Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. BMC Cancer (2013) 0.83
The effect of anterior proton beams in the setting of a prostate-rectum spacer. Med Dosim (2013) 0.83
Sensitivity analysis for lexicographic ordering in radiation therapy treatment planning. Med Phys (2012) 0.83
Interactive dose shaping part 2: proof of concept study for six prostate patients. Phys Med Biol (2016) 0.82
Proctitis following stereotactic body radiation therapy for prostate cancer. Radiat Oncol (2014) 0.82
Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer. Acta Oncol (2015) 0.82
Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Support Care Cancer (2013) 0.82
Displacements of fiducial markers in patients with prostate cancer treated with image guided radiotherapy: A single-institution descriptive study. Rep Pract Oncol Radiother (2014) 0.82
Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon. Radiat Oncol (2012) 0.81
Prediction of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer. Radiat Oncol (2015) 0.81
Prospective phase II study of image-guided local boost using a real-time tumor-tracking radiotherapy (RTRT) system for locally advanced bladder cancer. Jpn J Clin Oncol (2013) 0.81
Influence of image slice thickness on rectal dose-response relationships following radiotherapy of prostate cancer. Phys Med Biol (2014) 0.81
Reducing rectal injury during external beam radiotherapy for prostate cancer. Nat Rev Urol (2013) 0.80
Comparing four volumetric modulated arc therapy beam arrangements for the treatment of early-stage prostate cancer. J Med Radiat Sci (2014) 0.80
Accumulated dose to the rectum, measured using dose-volume histograms and dose-surface maps, is different from planned dose in all patients treated with radiotherapy for prostate cancer. Br J Radiol (2015) 0.80
Dosimetric evaluation of synthetic CT relative to bulk density assignment-based magnetic resonance-only approaches for prostate radiotherapy. Radiat Oncol (2015) 0.80
Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06. Radiother Oncol (2012) 0.79
A predictive model to guide management of the overlap region between target volume and organs at risk in prostate cancer volumetric modulated arc therapy. Radiat Oncol J (2014) 0.79
Radiation proctopathy. Clin Colon Rectal Surg (2015) 0.79
Superoxide dismutase mimic, MnTE-2-PyP(5+) ameliorates acute and chronic proctitis following focal proton irradiation of the rat rectum. Redox Biol (2013) 0.79
Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer. J Radiat Res (2014) 0.79
Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control. J Exp Clin Cancer Res (2013) 0.79
Retrospective evaluation of dosimetric quality for prostate carcinomas treated with 3D conformal, intensity modulated and volumetric modulated arc radiotherapy. J Med Radiat Sci (2013) 0.79
Preclinical Evaluation of Intraoperative Low-Energy Photon Radiotherapy Using Spherical Applicators in Locally Advanced Prostate Cancer. Front Oncol (2015) 0.78
Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions. Int J Radiat Oncol Biol Phys (2014) 0.78
Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction. Br J Radiol (2014) 0.78
Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. Acta Oncol (2015) 0.77
Focal therapy, differential therapy, and radiation treatment for prostate cancer. Adv Urol (2012) 0.77
Risk-adaptive volumetric modulated arc therapy using biological objective functions for subvolume boosting in radiotherapy. Comput Math Methods Med (2012) 0.77
mARC vs. IMRT radiotherapy of the prostate with flat and flattening-filter-free beam energies. Radiat Oncol (2014) 0.77
Strategic evaluation of interventions to prevent consequential late proctitis after prostate radiation therapy: new clinical trial designs should be considered. Cancer Biol Ther (2014) 0.77
Long-term Outcomes and Late Effects of Definitive Chemoradiotherapy in Patients with Cervical Cancer in Nova Scotia. Cureus (2015) 0.76
SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment. Strahlenther Onkol (2016) 0.76
Registering prostate external beam radiotherapy with a boost from high-dose-rate brachytherapy: a comparative evaluation of deformable registration algorithms. Radiat Oncol (2015) 0.76
Dependence of the safe rectum dose on the CTV-PTV margin size and treatment technique. Rep Pract Oncol Radiother (2015) 0.76
Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control. Cancer Med (2014) 0.76
Efficacy of Dose-Escalated Radiotherapy for Recurrent Colorectal Cancer. Ann Coloproctol (2016) 0.75
Helical tomotherapy of spinal chordomas: French Multicentric, retrospective study of a cohort of 30 cases. Radiat Oncol (2017) 0.75
Identifying radiation-induced survivorship syndromes affecting bowel health in a cohort of gynecological cancer survivors. PLoS One (2017) 0.75
Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer. Br J Radiol (2016) 0.75
PEG spacer gel and adaptive planning vs single plan in external prostate radiotherapy-clinical dosimetry evaluation. Br J Radiol (2015) 0.75
PET/CT-guided treatment planning for paediatric cancer patients: a simulation study of proton and conventional photon therapy. Br J Radiol (2014) 0.75
Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol (2016) 0.75
Can Anorectal Manometry Findings Predict Subsequent Late Gastrointestinal Radiation Toxicity in Prostate Cancer Patients? Cancer Res Treat (2015) 0.75
A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma. Radiat Oncol (2016) 0.75
Is the irradiated small bowel volume still a predictor for acute lower gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using intensity-modulated radiation therapy? Radiat Oncol (2015) 0.75
Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment. Br J Radiol (2015) 0.75
Improved beam angle arrangement in intensity modulated proton therapy treatment planning for localized prostate cancer. Cancers (Basel) (2015) 0.75
On voxel-by-voxel accumulated dose for prostate radiation therapy using deformable image registration. Technol Cancer Res Treat (2014) 0.75
International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer. Nagoya J Med Sci (2015) 0.75
Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles. J Med Radiat Sci (2016) 0.75
Equivalence of Gyn GEC-ESTRO guidelines for image guided cervical brachytherapy with EUD-based dose prescription. Radiat Oncol (2013) 0.75
Use of a correlation analysis model in the optimization of intensity-modulated radiotherapy of prostate cancer. Exp Ther Med (2015) 0.75
A modeling study of functional magnetic resonance imaging to individualize target definition of seminal vesicles for external beam radiotherapy. Acta Oncol (2017) 0.75
Evaluation of different set-up error corrections on dose-volume metrics in prostate IMRT using CBCT images. J Radiat Res (2014) 0.75
No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy. Br J Radiol (2016) 0.75
Parametrized rectal dose and associations with late toxicity in prostate cancer radiotherapy. Br J Radiol (2015) 0.75
Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer. Radiat Oncol (2016) 0.75
A Phase II Study to Prevent Radiation-induced Rectal Injury With Lovastatin. Am J Clin Oncol (2016) 0.75
Analysis of prostate bed motion using an endorectal balloon and cone beam computed tomography during postprostatectomy radiotherapy. Onco Targets Ther (2016) 0.75
Improved long-term outcomes with IMRT: is it better technology or better physics? Int J Radiat Oncol Biol Phys (2013) 0.75
Employing the therapeutic operating characteristic (TOC) graph for individualised dose prescription. Radiat Oncol (2013) 0.75
Delivery parameter variations and early clinical outcomes of volumetric modulated arc therapy for 31 prostate cancer patients: an intercomparison of three treatment planning systems. ScientificWorldJournal (2013) 0.75
An investigation of the dose distribution effect related with collimator angle in volumetric arc therapy of prostate cancer. J Med Phys (2016) 0.75
Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ≥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol (2016) 0.75
Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol. Syst Rev (2013) 0.75
Normal tissue studies in radiation oncology: A systematic review of highly cited articles and citation patterns. Oncol Lett (2014) 0.75
The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. PLoS One (2016) 0.75
Fiducial marker guided prostate radiotherapy: a review. Br J Radiol (2016) 0.75
Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med (2017) 0.75
A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Int J Clin Oncol (2016) 0.75
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys (1995) 15.12
Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys (1991) 13.16
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology (2000) 6.42
The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care (1998) 4.34
Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys (1991) 3.64
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 3.61
Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys (2008) 3.22
Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys (2004) 3.10
Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys (2005) 2.31
Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys (2004) 2.16
Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys (1999) 1.89
Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys (2003) 1.88
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.85
Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys (2000) 1.71
Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.71
Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys (1997) 1.65
Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.58
Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol (2004) 1.57
Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys (2006) 1.50
Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys (2007) 1.43
Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys (2001) 1.39
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys (2010) 1.35
Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol) (2007) 1.33
Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys (2006) 1.29
Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol (2001) 1.28
Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys (2007) 1.23
Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys (2002) 1.15
Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys (2000) 1.14
Is there more than one late radiation proctitis syndrome? Radiother Oncol (1999) 1.14
Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys (2003) 1.13
Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.11
Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.05
Dose-wall histograms and normalized dose-surface histograms for the rectum: a new method to analyze the dose distribution over the rectum in conformal radiotherapy. Int J Radiat Oncol Biol Phys (1999) 1.03
Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum. Int J Radiat Oncol Biol Phys (2005) 0.90
Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA (2009) 9.47
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 6.98
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33
Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys (2010) 3.73
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 3.61
Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys (2004) 3.21
Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2005) 3.19
Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys (2006) 2.82
Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys (2002) 2.76
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol (2009) 2.75
Prescribing radiation dose to lung cancer patients based on personalized toxicity estimates. J Thorac Oncol (2012) 2.61
Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol (2007) 2.56
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2007) 2.28
Lipid bilayer structure determined by the simultaneous analysis of neutron and X-ray scattering data. Biophys J (2008) 2.27
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes Chromosomes Cancer (2003) 2.24
Telomeric expression sites are highly conserved in Trypanosoma brucei. PLoS One (2008) 2.22
Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol (2003) 2.19
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol (2008) 2.17
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J (2003) 2.11
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res (2005) 2.09
Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol (2008) 2.08
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer (2004) 2.02
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys (2005) 2.02
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys (2009) 2.01
Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int J Radiat Oncol Biol Phys (2009) 1.97
Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.94
Equatorially dominated magnetic field change at the surface of Earth's core. Science (2003) 1.94
A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys (2007) 1.90
Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys (2006) 1.85
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther (2006) 1.84
Progress toward a microradiation therapy small animal conformal irradiator. Med Phys (2006) 1.84
GeneDB--an annotation database for pathogens. Nucleic Acids Res (2011) 1.82
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.74
Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res (2004) 1.70
Analyzing habituation responses to novelty in zebrafish (Danio rerio). Behav Brain Res (2009) 1.69
Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys (2006) 1.67
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys (2010) 1.67
Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.65
The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys (2010) 1.65
Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys (2004) 1.64
FGF9 suppresses meiosis and promotes male germ cell fate in mice. Dev Cell (2010) 1.64
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys (2005) 1.63
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol (2009) 1.59
Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer (2005) 1.57
Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.56
Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol (2005) 1.53
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys (2002) 1.51
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.51
Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.49
4D-CT motion estimation using deformable image registration and 5D respiratory motion modeling. Med Phys (2008) 1.49
Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys (2010) 1.46
The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys (2012) 1.46
Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys (2003) 1.45
Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. Int J Radiat Oncol Biol Phys (2010) 1.44
Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiother Oncol (2008) 1.40
A novel small-angle neutron scattering detector geometry. J Appl Crystallogr (2013) 1.39
Estimating the volume of chronic pleural effusions using transesophageal echocardiography. J Cardiothorac Vasc Anesth (2011) 1.39
An autonomous implantable computer for neural recording and stimulation in unrestrained primates. J Neurosci Methods (2005) 1.38
Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys (2011) 1.37
Learning a novel myoelectric-controlled interface task. J Neurophysiol (2008) 1.36
International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer (2002) 1.36
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol (2005) 1.33
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol (2007) 1.32
IMRT treatment planning based on prioritizing prescription goals. Phys Med Biol (2007) 1.32
Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys (2008) 1.32
Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys (2010) 1.30
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol (2012) 1.29
A fast inverse consistent deformable image registration method based on symmetric optical flow computation. Phys Med Biol (2008) 1.29
Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys (2004) 1.29
Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys (2005) 1.29
Accurate accumulation of dose for improved understanding of radiation effects in normal tissue. Int J Radiat Oncol Biol Phys (2010) 1.28
Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer (2006) 1.28
Concurrent multimodality image segmentation by active contours for radiotherapy treatment planning. Med Phys (2007) 1.26
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol (2004) 1.25
Extracorporeal membrane oxygenation for severe ARDS in pregnant and postpartum women during the 2009 H1N1 pandemic. Intensive Care Med (2011) 1.22
Seven consecutive successful clinical islet isolations with pancreatic ductal injection. Cell Transplant (2009) 1.21
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol (2002) 1.20
Methodological issues in radiation dose-volume outcome analyses: summary of a joint AAPM/NIH workshop. Med Phys (2002) 1.20
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.20
African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer (2006) 1.20
Heart irradiation as a risk factor for radiation pneumonitis. Acta Oncol (2010) 1.20
Identification of extracellular delta-catenin accumulation for prostate cancer detection. Prostate (2009) 1.19
Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys (2007) 1.17
Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.17
Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int J Cancer (2002) 1.16
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res (2012) 1.16
Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int J Radiat Oncol Biol Phys (2010) 1.14
Flexible cortical control of task-specific muscle synergies. J Neurosci (2012) 1.14
Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer. Int J Radiat Oncol Biol Phys (2012) 1.13